WALTHAM, Mass., Feb. 2, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases, announced today that CEO John A.
Kollins will present a corporate overview and update at the BIO CEO and
Investor Conference on Monday, February 9th, at 2:45 p.m. EST (11:45 a.m. PST),
in the Waldorf-Astoria hotel's Conrad Suite in New York City, NY. An archived
webcast of the presentation can be accessed for 30 days following the
presentation under the Investor Center tab at www.oxigene.com.
About OXiGENE, Inc.
OXiGENE is a clinical-stage biotechnology company developing novel
small-molecule therapeutics to treat cancer and eye diseases. The Company's
major focus is the clinical advancement of drug candidates that selectively
disrupt abnormal blood vessels associated with solid tumor progression and
visual impairment. OXiGENE is dedicated to leveraging its intellectual property
position and therapeutic development expertise to bring life saving and
enhancing medicines to patients.
CONTACT: OXiGENE
Investor and Media Contact:
Michelle Edwards, Investor Relations
medwards@oxigene.com
415-315-9413
OXiGENE to Present At BIO CEO and Investor Conference On February 9, 2009
| Source: Oxigene, Inc.